Objective
To compare TAVI with SAVR in patients who were at low or intermediate surgical risk and eligible for both treatment strategies in a real-world setting
Study
Investigator-initiated, open label, randomised-controlled trial
Population
Patients with severe, symptomatic aortic stenosis at low or intermediate surgical risk aged over 65 years
Endpoints
Composite of death from any cause or fatal or nonfatal stroke at 1 year
Conclusion
TAVI was noninferior to SAVR with respect to death from any cause or stroke at 1 year.
Blankenberg et al. N Engl J Med. 2024
